Heron Therapeutics Inc (HRTX) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
Heron Therapeutics, Inc. (HRTX)
Last heron therapeutics, inc. earnings: 3/2 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
herontherapeutics.gcs-web.com/investor-home
Company Research
Source: Yahoo! Finance
Adjusted EBITDA (Full Year 2024): $8.6 million. CINVANTI Net Revenues (Q4 2024): $26.9 million, up from $22.7 million in Q3. CINVANTI Net Revenues (Full Year 2024): Just over $100 million, up from $94.8 million in 2023. ZYNRELEF Net Revenues (Q4 2024): $8.5 million, a 33% increase from $6.3 million in Q3. Gross Margin (Full Year 2024): Improved from 49% to approximately 73%. Operating Expenses Reduction: Reduced by over $80 million since 2022. Cash Balance (End of 2024): Just over $59 million. SG&A Expenses (Q4 2024): $23.2 million, down from $26.8 million in Q4 2023. Research and Development Expenses (Q4 2024): $3.2 million, down from $7.8 million in Q4 2023. Net Loss (Full Year 2024): $13.6 million, improved from a net loss of $110.6 million in 2023. Cash and Short-term Investments (End of 2024): $59.3 million. Product Revenues Net Guidance (2025): $153 million to $163 million. Adjusted EBITDA Guidance (2025): $0 to $8 million. Warning! GuruFocus has detec
Show less
Read more
Impact Snapshot
Event Time:
HRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HRTX alerts
High impacting Heron Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HRTX
News
- Heron Therapeutics, Inc. (NASDAQ:HRTX) is favoured by institutional owners who hold 57% of the company [Yahoo! Finance]Yahoo! Finance
- Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)GlobeNewswire
- Heron Therapeutics: Stagnant Cash Cow, Blockbuster That Wasn't - Steer Clear [Seeking Alpha]Seeking Alpha
- Heron Therapeutics (NASDAQ:HRTX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..MarketBeat
- Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial ProgressGlobeNewswire
HRTX
Earnings
- 11/4/25 - Miss
HRTX
Sec Filings
- 11/26/25 - Form SCHEDULE
- 11/12/25 - Form 4
- 11/7/25 - Form 3
- HRTX's page on the SEC website